Data support request for Emergency Use Authorization of a 30-µg booster dose of an Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine for individuals 12 years of age […]
… For Adolescents 12 through 15 Years of Age COMIRNATY® is the first and only COVID-19 vaccine to be granted FDA approval for adolescents 12 […]
…. for the Vaccination of Children Ages 6 Months to less than 5 Years with COMIRNATY® Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: […]
BioNTech values and respects valid intellectual property rights. BioNTech’s work is original, and we will vigorously defend it against all allegations of patent infringement. However, […]
In a Phase 2/3 clinical trial, the Pfizer-BioNTech COVID-19 Vaccine elicited a strong immune response in this age group Three 3-µg doses had favorable safety […]
and Other Virus Variants Effectively Replenished after 3rd and 4th COVID-19 Vaccination 12 / 2022 Two vaccinations with Comirnaty do not lead to adequate antibody […]
Submission based on real-world safety and efficacy data from Israel Data showed rates of confirmed infections were 2 times lower and rates of severe illness […]
Ugur Sahin, CEO and Co-Founder of BioNTech: “We at BioNTech are closely following the tragic situation in Ukraine and our thoughts are with everyone affected. […]
Your Excellency President Macron,Excellency President Macky Sall,Excellency President Abdel Fattah Al-Sisi,Excellency President Kenyatta,Excellency President Buhari,Excellency President Saied,Excellency President Michel,Excellency President von der Leyen,Excellencies, dear colleagues, […]
Developing turnkey solution to enable mRNA-based vaccine production in modular and scalable sites installed by BioNTech Presidents of Ghana, Rwanda, Senegal, the Director-General of the […]
With pediatric COVID-19 cases surpassing 10 million and at the request of the FDA, the companies have submitted available data on the safety and efficacy […]
On 15 January 2021, a shipment of 1.1 million COVID-19 vaccines to Rwanda included the billionth dose supplied via COVAX. Together with our partners, COVAX […]
Interim Statement on COVID-19 vaccines in the context of the circulation of the Omicron SARS-CoV-2 Variant from the WHO Technical Advisory Group on COVID-19 Vaccine […]
Early Warning System combines Spike protein structural modeling with artificial intelligence (AI) to detect and monitor high-risk SARS-CoV-2 variants, identifying >90% of WHO-designated variants on […]
Merck has signed a definitive agreement to acquire Exelead, a biopharmaceutical contract development and manufacturing organization (CDMO), for approximately USD 780 million in cash. Targeted […]
Copyright © 2022 | WordPress Theme by MH Themes
